23
July 21 – Novartis' second-quarter core operating profit beat market expectations on Tuesday, helped by strong sales of cancer and multiple sclerosis drugs. The Swiss drugmaker saw quarterly group
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)
